Edition:
United States

Sun Pharmaceutical Industries Ltd (SUN.BO)

SUN.BO on Bombay Stock Exchange

719.45INR
2 Dec 2016
Change (% chg)

Rs-2.35 (-0.33%)
Prev Close
Rs721.80
Open
Rs721.00
Day's High
Rs730.75
Day's Low
Rs715.25
Volume
265,408
Avg. Vol
378,117
52-wk High
Rs898.00
52-wk Low
Rs572.40

SUN.BO

Chart for SUN.BO

About

Sun Pharmaceutical Industries Limited is a pharmaceuticals company. The Company's business segments include US Business, Indian Branded Generics Business, Emerging Markets, Global Consumer Healthcare Business and Active Pharmaceutical Ingredients (API). Its Rest of World segment includes Western Europe, Canada, Australia, New... (more)

Overall

Beta: 0.36
Market Cap(Mil.): Rs1,661,461.00
Shares Outstanding(Mil.): 2,406.69
Dividend: 1.00
Yield (%): 0.14

Financials

  SUN.BO Industry Sector
P/E (TTM): 22.52 29.13 29.87
EPS (TTM): 30.66 -- --
ROI: 23.32 15.56 14.95
ROE: 22.83 16.69 16.29

BRIEF-Sun Pharma Industries launches first branded ophthalmic product Bromsite in USA

* Announcement of launches first branded ophthalmic product Bromsite in USA

Nov 28 2016

BRIEF-Sun Pharma enters into deal to buy 85.1 pct of Russia's JSC Biosintez

* Says company has entered into an agreement to acquire 85.1% of JSC Biosintez, a Russian pharmaceutical company

Nov 22 2016

UPDATE 2-Sun Pharma expects U.S. drug pricing pressures to continue

* Says expects pricing pressure in U.S. to continue (Adds comments from conference call)

Nov 10 2016

BRIEF-India's Sun Pharma says unsure if Halol plant will be cleared in next 5 months

* India's Sun Pharma said it was unsure if Halol plant would be cleared in the next five months, as the FDA may take time Further company coverage: (Reporting By Zeba Siddiqui)

Nov 10 2016

BRIEF-Sun Pharmaceutical Industries exec says pricing pressure in the U.S. will continue

* Sun Pharmaceutical Industries exec says awaiting US FDA reinspection of Halol plant

Nov 10 2016

India's Sun Pharma Q2 profit beats estimates

MUMBAI, Nov 10 Sun Pharmaceutical Industries Ltd , India's largest drugmaker, reported on Thursday a quarterly profit that more than doubled from last year, outpacing analysts' expectations.

Nov 10 2016

BRIEF-Sun Pharmaceutical Industries approves amalgamation of 4 units into co

* Says approves scheme of amalgamation of Sun Pharma Medisales, Ranbaxy Drugs Ltd, Gufic Pharma, Vidyut Investments into co Source text: http://bit.ly/2g0Jbpb Further company coverage:

Nov 10 2016

BRIEF-Sun Pharmaceutical Industries on track to achieve benefits from Ranbaxy acquisition

* Sun Pharmaceutical Industries Ltd says synergies from the Ranbaxy acquisition are gaining momentum and co on track to achieve the targeted benefits

Nov 10 2016

BRIEF-Sun Pharmaceutical Industries Sept-qtr profit more than doubles

* Consensus forecast for Sep-qtr consol profit was 16.46 billion rupees

Nov 10 2016

BRIEF-Tianjin Chase Sun Pharma to invest 170 mln yuan in biopharma technology firm in Jiangsu

* Says it signs agreement to invest 170 million yuan ($25.09 million) in biopharma technology firm in Jiangsu province

Nov 09 2016

Earnings vs. Estimates